Ipamorelin + CJC-1295 (No DAC)
Price range: £54.00 through £74.00
CAS: 170851-70-4
Strengths Available: 5/5mg
Format: Sealed containment / vial presentations available
Volume: 3mL
What Ipamorelin / CJC-1295 (No-DAC) is about
The Ipamorelin / CJC-1295 (No-DAC) combination is one of the most widely referenced pairings in growth hormone research. It brings together two complementary signalling peptides that stimulate endogenous growth hormone release through distinct but cooperative pathways. This combination is frequently discussed in research exploring physiological growth hormone pulse patterns, endocrine regulation, and metabolic signalling. What’s in This Combination? Ipamorelin (5mg) A selective ghrelin receptor agonist studied for its ability to stimulate growth hormone release with minimal impact on other hormonal pathways. CJC-1295 Non-DAC (2mg) A short-acting analogue of Growth Hormone Releasing Hormone (GHRH) studied for its role in initiating natural growth hormone pulses.
Description
What’s in This Combination?
Ipamorelin (5mg)
A selective ghrelin receptor agonist studied for its ability to stimulate growth hormone release with minimal impact on other hormonal pathways.
CJC-1295 Non-DAC (2mg)
A short-acting analogue of Growth Hormone Releasing Hormone (GHRH) studied for its role in initiating natural growth hormone pulses.
Why Researchers Study This Combination
- Exploration of complementary growth hormone signalling pathways
- Study of natural, pulse-based growth hormone release
- Investigation of endocrine regulation and feedback mechanisms
- Comparison with single-agent growth hormone secretagogues
- Research into metabolic and recovery-related signalling
What the Research Suggests
Research literature has shown that Ipamorelin and CJC-1295 act through separate receptors involved in growth hormone regulation, allowing for coordinated stimulation of hormone release. Interest in this pairing stems from its ability to model physiological growth hormone patterns more closely than single-pathway stimulation. These findings describe biological signalling observed in research environments and do not represent approved medical or performance-enhancing claims.
Scientific Background and Mechanism of Action of Ipamorelin + CJC-1295 (No DAC)
Ipamorelin and CJC-1295 without DAC are synthetic research peptides commonly studied together because they act on complementary parts of the growth hormone signalling pathway.
Ipamorelin is a growth hormone secretagogue that mimics ghrelin-like signalling, while CJC-1295 without DAC is a growth hormone-releasing hormone analogue. Together, they are studied for their combined influence on growth hormone release, pituitary signalling, metabolic regulation, and body-composition research.
Scientific Background
Growth hormone release is controlled mainly by two biological signals: growth hormone-releasing hormone, which stimulates release, and somatostatin, which inhibits release. Ghrelin-related signalling can also stimulate growth hormone secretion through the growth hormone secretagogue receptor.
CJC-1295 without DAC is designed to act through the GHRH receptor, supporting pituitary stimulation in a way that resembles natural GHRH signalling. The “No DAC” form does not include the drug affinity complex, meaning it has a shorter duration of action compared with DAC-modified versions.
Ipamorelin is studied as a selective ghrelin receptor agonist. It is of interest because research suggests it may stimulate growth hormone release while having less activity on other hormonal pathways compared with some earlier growth hormone secretagogues.
Mechanism of Action
Ipamorelin and CJC-1295 without DAC are studied together because they may support growth hormone release through two separate but complementary mechanisms.
CJC-1295 without DAC works by activating the GHRH receptor on pituitary somatotroph cells. This encourages the pituitary gland to release growth hormone in response to GHRH-like signalling.
Ipamorelin works through the growth hormone secretagogue receptor, also known as the ghrelin receptor. This pathway can further stimulate pituitary growth hormone release and may support a more amplified pulse-like response when studied alongside GHRH analogues.
Because these pathways are different, the combination is often researched for its potential to produce a coordinated growth hormone response without directly supplying growth hormone itself.
Research Context
Ipamorelin + CJC-1295 without DAC is commonly studied in relation to:
- Growth hormone pulse regulation
- Pituitary signalling
- IGF-1 response pathways
- Body-composition research
- Protein metabolism
- Recovery and tissue-repair signalling
- Age-related endocrine changes
- Metabolic function
- Muscle and connective-tissue research
The combination has attracted scientific interest because it allows researchers to study upstream stimulation of the growth hormone axis rather than direct growth hormone administration. This makes it relevant for investigations into endocrine feedback, natural pulse patterns, and hormone-regulated metabolic processes.
Ongoing Scientific Interest
Ongoing research interest in Ipamorelin + CJC-1295 without DAC focuses on how GHRH and ghrelin-receptor pathways interact within the somatotropic axis. Researchers continue to explore how these peptides may influence growth hormone release patterns, downstream IGF-1 signalling, cellular repair pathways, and metabolic regulation.
Overall, Ipamorelin + CJC-1295 without DAC is best understood as a research peptide combination used to study growth hormone secretagogue biology, pituitary response, endocrine signalling, and body-composition-related pathways.
For research and laboratory use only. Not for human or veterinary use.
Ingredient Profile
Single research compound: Ipamorelin + CJC-1295 (No DAC)
CAS: 170851-70-4
Purity >99%
Supplied as lyophilised powder (no excipients, fillers or additives).
Active Ingredients
Ipamorelin + CJC-1295 (No DAC) — 5mg / 5mg
Ingredient Breakdown
Blend components: Ipamorelin + CJC-1295 (No DAC). Per-vial strengths: 5mg / 5mg.
Why are Ipamorelin and CJC-1295 often studied together?
Because they stimulate growth hormone release through complementary receptor pathways.
What does Non-DAC mean in this context?
Non-DAC refers to the short-acting form of CJC-1295 that produces pulse-based signalling.
Does this combination replace growth hormone?
No. It is studied for stimulating endogenous growth hormone release rather than replacing it.
Is this combination approved for medical use?
No. It is supplied strictly for research and laboratory investigation only.
Why is pulse-based signalling important in research?
Because it more closely resembles natural physiological hormone release patterns.
Can the components be studied independently?
Yes. Each component may be studied individually or together depending on experimental design.
Why does purity matter in combination research?
High purity ensures that observed effects can be attributed to each peptide accurately.
What does research grade mean?
It indicates batch traceability and documentation suitable for laboratory work.
Does the sealed containment device indicate dosing?
No. It provides an analytical reference only and is not instructions for use.
Can this combo be supplied internationally?
Yes. International fulfilment and temperature-controlled shipping can be supported where appropriate.
Research & laboratory use only. Not for human or veterinary use. Not a medicinal product, supplement, food or medical device. No therapeutic, diagnostic, cosmetic, wellness or lifestyle claims are made or implied. Analytical reference/click information is a laboratory measurement aid only and must not be applied to living systems.
Typically supplied at >99% purity, supported by batch-specific analytical data. UK-based preparation, analysis and release under scientist-led, GMP-aligned processes with full batch-level traceability. Certificate of Analysis (CoA) available on request; independent analytical verification where appropriate.
Store the lyophilised powder refrigerated at 2–8°C, protected from light and moisture; suitable for longer-term storage frozen at -20°C. Handle under appropriate laboratory conditions. For in vitro research use only.
For in vitro laboratory research only. Reconstitution, handling and experimental design at the discretion of the qualified researcher. The 300-click sealed-containment system is an analytical measurement reference only and does not represent dosing or administration guidance. Not for use in living systems.
Partner with FreshstartPharma– Where Accuracy Meets Innovation
Freshstartpharma is committed to delivering high-quality research-grade products designed for advanced scientific applications. We offer wholesale partnerships to selected businesses that share our values of integrity, quality, and innovation. Whether you’re an established distributor or an emerging research supply company, we invite you to join our network and benefit from exclusive access to our state-of-the-art product range.
Related Products
KPV
FRAG
KLOW
